AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 133 min read$VNRX

VOLITIONRX LTD (VNRX): Results of Operations and Financial Condition

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. vnrx_8k.htm 0000093314 false 0000093314 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 D

Original reporting
SEC EDGAR 8-K
Published Aug 13, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$VNRX
Neutral
low confidence
Mentioned
$VNRX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VNRXNeutralLow
01

Why it matters

The filing itself is a procedural disclosure that typically precedes market repricing once investors digest the actual earnings metrics and any guidance or operational updates in the attached press release.

02

Market read

This sets up an earnings-event window for VNRX, but the provided text does not include the figures needed to forecast direction.

03

What to watch

The key driver is likely the content of Exhibit 99.1 (financials and business updates). The scraped body omits those details, so the real trading signal may be missed.

Relevance 7/10Novelty 2/10Timing: Filed Aug 13, 2026, with conference call scheduled for Aug 14, 2026 premarket/market hours depending on local timing.

Background

The SEC 8-K (Item 2.02) states VolitionRx issued a press release with financial results and business updates for the quarter ended June 30, 2026, and confirmed a conference call for Aug 14, 2026.

Company-level read

Ticker impact

$VNRXNeutralLow confidence
Context

VolitionRx filed an 8-K furnishing its quarter ended June 30, 2026 results press release and scheduled an Aug 14, 2026 call.

Expected impact

Near-term volatility possible into the Aug 14 conference call, but direction cannot be inferred from the provided text.

Evidence & confidence

The filing confirms the existence of a results press release and call timing, yet provides no numbers, guidance, or qualitative outcomes in the article body.

Market effects

Sector

Limited read-through because the article body does not disclose trial, regulatory, or product milestones.

Regional

Minimal, as this is a single-company SEC filing without disclosed macro drivers.

Global

Low, no cross-border deal, regulation, or supply-chain event is described.

Counterpoint

What could challenge this read

Traders may overreact to the mere presence of an 8-K, but without the actual results/guidance in the text, the filing alone is not a directional catalyst.

Key entities

  • issuer
    VolitionRx Limited

    Company filing the 8-K and furnishing Exhibit 99.1 with quarterly results and business updates.

  • executive
    Cameron Reynolds

    CEO and President signing the 8-K.

Read at source← All news

Related articles

AUG 13
$VNRXMed

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

prnewswire.com4 min
AUG 13
$CPKMedAI 8/10

Chesapeake Utilities (CPK) Q2 2026 Earnings Call Transcript

Chesapeake Utilities (CPK) reported Q2 2026 adjusted net income of $25.4 million, up 5% year over year, and adjusted EPS of $1.05. Management raised 2026 capital guidance to $550 million to $600 million and expects 2028 EPS of $7.75 to $8.00. It also discussed the $1.2 billion Florida Energy Pathway project and reaffirmed efficiency and dividend plans.

fool.com10 min
AUG 13
$QNSTHighAI 9/10

QuinStreet (QNST) Q4 2026 Earnings Call Transcript

QuinStreet (QNST) reported Q4 FY2026 revenue of $373.9M, up 43% y/y, and full-year revenue of $1.3B, up 18% y/y, driven by Financial Services and Home Services. Adjusted EBITDA rose to $41.4M (11.1% margin). Non-GAAP EPS was $0.50 in Q4. Q1 2027 revenue guidance is $370M-$380M.

fool.com7 min
AUG 13
$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

fool.com7 min
AUG 13
$NUTXMedAI 8/10

Nutex Health (NUTX) Q2 2026 Earnings Call Transcript

Nutex Health (NUTX) reported Q2 2026 results on an earnings call. Total revenue fell to $210.8M from $244.0M. Net income rose to $65.8M, diluted EPS to $9.38, and adjusted EBITDA to $90.0M. Management cited lower contract services costs from a HaloMD amendment and higher patient visits, plus a hospital expansion pipeline.

fool.com7 min
AUG 13
$ALRMMedAI 9/10

Alarm.com (ALRM) Q2 2026 Earnings Call Transcript

Alarm.com (ALRM) reported Q2 2026 results. SaaS and license revenue was $188.8 million, up 11.1% YoY and above guidance midpoint. Total revenue rose 9.2% to $277.7 million. Non-GAAP adjusted EBITDA was $57.7 million, up 15.7%, and adjusted EPS was $0.77. Full-year guidance was raised for SaaS, total revenue, and adjusted EBITDA.

fool.com7 min